Overlay Tool© for aCGHViewer©: An Analysis Module Built for aCGHViewer© used to Perform Comparisons of Data Derived from Different Microarray Platforms by Lo, Ken C. et al.
Cancer Informatics 2007:3 307–319 307
ORIGINAL RESEARCH
Correspondence: John K. Cowell, Ph.D., D.Sc. FRCPath, Department of Cancer Genetics, Roswell Park 
Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Tel: (716)845-5714; Fax: (716)845-1698; 
Email: john.cowell@roswellpark.org
Please note that this article may not be used for commercial purposes. For further information please refer to the  copyright 
statement at http://www.la-press.com/copyright.htm
Overlay Tool
© for aCGHViewer
©: An Analysis Module Built 
for aCGHViewer
© used to Perform Comparisons of Data 
Derived from Different Microarray Platforms 
Ken C. Lo
1, Ganesh Shankar
1, Yaron Turpaz
2, Dione Bailey
2, Michael R. Rossi
1,3, 
Tania Burkhardt
1, Ping Liang
1 and John K. Cowell
1
1Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263. 
2Affymetrix, Inc. 
Santa Clara, CA 95051. 
3Yale University School of Medicine, Department of Cancer Genetics, New 
Haven, CT 06520. 
Abstract: The Overlay Tool
© has been developed to combine high throughput data derived from various microarray platforms. 
This tool analyzes high-resolution correlations between gene expression changes and either copy number abnormalities 
(CNAs) or loss of heterozygosity events detected using array comparative genomic hybridization (aCGH). Using an overlay 
analysis which is designed to be performed using data from multiple microarray platforms on a single biological sample, 
the Overlay Tool
© identiﬁ  es potentially important genes whose expression proﬁ  les are changed as a result of losses, gains 
and ampliﬁ  cations in the cancer genome. In addition, the Overlay Tool
© will incorporate loss of heterozygosity (LOH) 
probability data into this overlay procedure. To facilitate this analysis, we developed an application which computationally 
combines two or more high throughput datasets (e.g. aCGH/expression) into a single categorized dataset for visualization 
and interrogation using a gene-centric approach. As such, data from virtually any microarray platform can be incorporated 
without the need to remap entire datasets individually. The resultant categorized (overlay) data set can be conveniently 
viewed using our in-house visualization tool, aCGHViewer
© (Shankar et al. 2006), which serves as a conduit to public 
databases such as UCSC and NCBI, to rapidly investigate genes of interest. 
Keywords: Overlay Analysis, Microarray, ACGH, expression proﬁ  ling, CNAs, aCGHViewer.
Introduction
Cytogenetic abnormalities are consistently associated with the development of the tumor phenotype and 
have been used extensively as diagnostic and prognostic tools (Sandberg, 1980). The development of 
Comparative Genome Hybridization (CGH) by Kallionemi et al. (1992) provided a cost-effective and 
efﬁ  cient method of identifying copy number aberrations (CNAs) across the entire genome without the 
need for metaphase chromosomes from the tumor cells. With the recent evolution of CGH onto a micro-
array platform (aCGH), large-scale high-resolution studies can now be performed with small DNA 
samples, accelerating the discovery process for molecular mechanisms of tumorigenesis and progression. 
One aCGH platform that is now widely used involves large insert clones such as bacterial artiﬁ  cial chro-
mosomes (BACs), although oligonucleotide arrays have also been developed (Carvalho et al. 2004). 
One of the confounding problems of using these aCGH approaches to study CNAs on a genome 
wide basis is that it is often difﬁ  cult to discern those losses/gains/ampliﬁ  cations that are ‘real’ discov-
eries from artifacts introduced either by the technology or as a result of, for example, mismapped BACs 
(Rossi et al. 2005) or BACs that are located in regions that are inherently polymorphic for copy number 
(Iafrate et al. 2004). In an attempt to resolve these issues, numerous statistical approaches have been 
developed to assess the relative copy number in each segment of the genome, while controlling the 
false discovery rate (FDR). These approaches include Hidden Markov Model, Circular Binary Segmen-
tation (CBS), quantile smoothing, Bayesian, adaptive weights smoothing, clustering, and heuristic 
smoothing methods (Olshen et al. 2004; Eilers and Menezes, 2005; Daruwala et al. 2004; Hupe et al. 
2004; Wang et al. 2005; Jong et al. 2004). While these methods accurately identify abnormal regions, 
the aCGH platform can only provide insights into copy number aberrations. With the discovery of these 
aberrations, numerous follow-up questions are raised. For example, when a segment of the genome is 
ampliﬁ  ed/deleted, what are the biological consequences? Generally, when a segment containing a known 308
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oncogene is ampliﬁ  ed, the resulting ampliﬁ  cation 
presumably leads to an overexpression of that 
oncogene, driving tumor growth/progression. In 
most circumstances, these observations are 
conﬁ  rmed independently using non-array based 
gene expression veriﬁ  cation. However, since large 
segment CNAs contain many genes, prioritizing 
which ones to verify can be difﬁ  cult. Ideally, given 
unlimited resources and manpower, all genes 
within ampliﬁ  cations/deletions would be indepen-
dently veriﬁ  ed, but this is a time consuming and 
labor-intensive endeavor that is often cost-
prohibitive on a gene-by-gene basis.
Another platform that is widely adopted to study 
genes associated with cancer involves gene 
expression proﬁ  ling using oligonucleotide arrays. 
Essentially, genes associated with tumorigenesis 
can be identiﬁ  ed by comparing expression patterns 
between normal and tumor samples. These arrays 
allow the simultaneous evaluation of gene 
expression levels of over 54,000 probe sets (using 
the Affymetrix GeneChips
 ® U133 Plus 2 array, for 
example) in a single experiment. As with aCGH, 
statistical methods such as analysis of variance 
(ANOVA) (reviewed by Cui and Churchill, 2003), 
as well as Signiﬁ  cant Analysis of Microarrays 
(SAM) (Tusher et al. 2001), and Principle 
Component Analysis (PCA) (Yeung et al. 2001) 
have been used to eliminate genes which either do 
not show signiﬁ  cant changes or are not associated 
with the hypothesis. Again, the question remains 
whether the gene expression variation reﬂ  ects true 
biological differences, or systematic noise? The 
problem is more signiﬁ  cant for the Affymetrix 
platforms since generation of this data does not use 
comparative co-hybridization with matching 
normal samples to control for variation. Thus, 
small ﬂ  uctuations during the various stages of 
establishing the gene expression proﬁ  le may intro-
duce additional noise into the system. To overcome 
this problem, Affymetrix has incorporated several 
design features such as the Perfect Match/Mismatch 
probe sets to lower the FDR, as well as the 
development of new statistical analysis algorithms 
to increase the robustness of normalization and 
analysis. Despite these advancements, a typical 
experiment will generally identify statistically 
signiﬁ  cant candidate genes that are too numerous 
to be veriﬁ  ed individually.
One way to assess the relative importance of 
gene expression changes is to combine the analysis 
of two different platforms from the same biological 
samples. This overlay analysis can potentially 
identify genes within speciﬁ  c chromosomal regions 
that demonstrate CNA or loss of heterozygosity 
(LOH) with corresponding increases or decreases 
in expression, thereby providing a ﬁ  lter to deter-
mine the ‘drivers’ of the CNA/LOH. This follows 
since it is perceived that tumors gain increased 
malignancy as a result of acquiring selective chro-
mosomal gains/losses, or LOH, as mechanisms for 
altering gene function/expression. The underlying 
advantage of this approach is the high throughput 
identiﬁ  cation of potential changes in gene expres-
sion with associated mechanism, which then 
increases the robustness of either platform by 
itself. 
Due to the data-intensive nature of each of the 
high-throughput platforms, computational overlay 
of datasets required the development of speciﬁ  c 
software to achieve our goal. To this end, we have 
developed an application that can combine multiple 
datasets by establishing agreement between 
complementary platforms. This program outputs 
a tab-delimited text ﬁ  le to be used with our in-
house visualization tool, aCGHViewer
© (Shankar 
et al. 2006), as well as providing access to the raw 
data through a summary user-interface.
Results
Development of the Overlay Tool
©
At the time of preparation of this manuscript, no 
standard approach for combining data from aCGH 
and expression arrays was publicly available. The 
biological question we are attempting to address 
focuses on selective pressure gained within the 
conﬁ  nes of a copy number aberration or region of 
LOH. For example, when an ampliﬁ  cation event 
is observed, which genes in the amplicon are 
upregulated that can be investigated for their 
potential to confer growth advantage to a tumor 
cell? Recently, work in our group has demon-
strated that, within a given amplicon, only certain 
subsets of the genes within that region are 
upregulated (Rossi et al. 2005). The assumption 
is that only ‘drivers’ that contribute to tumor 
growth/progression are overexpressed (and 
selected for) in an amplicon, while bystanders are 
not overexpressed since they have no selective 
advantage (or were simply not actively expressed 
in that tissue in the ﬁ  rst place). Due to the data-
intensive nature of high throughput technology, 309
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however, manually combining the raw data 
between the two platforms became too labor inten-
sive to perform even on relatively small sample 
sizes. To overcome this limitation of data analysis, 
we developed an analysis protocol implemented 
in Microsoft
® Visual Basic 2005
® to computation-
ally combine the two datasets and assign a cate-
gory type based on agreement/disagreement 
between the multiple datasets from the aCGH, 
oligonucleotide based expression platforms and 
oligonucleotide based SNP arrays. This tool has 
been named the RPCI Overlay Tool
©™.
As part of the developmental process for the 
aCGHViewer
© (Shankar et al. 2006), the Overlay 
Tool
© is the ﬁ  rst analysis application designed for 
the aCGHViewer
© pipeline, which takes advantage 
of the category ﬂ  agging capability inherent in 
aCGHViewer
© to highlight major changes when 
agreement is found between datasets. In this case, 
overexpressed genes caused by ampliﬁ  cation, or 
down-regulated genes caused by deletions, are 
denoted as signiﬁ  cant changes and are displayed 
in aCGHViewer
© as red (gains/overexpression) or 
green (losses/downregulation).
Implementation and features
The Overlay Tool
© is implemented as a stand-alone 
application, with a tab-delimited output that is 
speciﬁ  cally designed to be visualized within the 
aCGHViewer
© (Shankar et al. 2006). Currently, 
the Overlay Tool
© requires at least 128Mb of RAM, 
Microsoft
® .NET Framework 2.0, Microsoft
® 
Windows 2000
® operating system or above, and 
J2SE
® 1.3 or greater (full install, not just the JRE 
for aCGHViewer
©) to run. The option to query the 
raw data (at the summary level) is achieved via a 
summary user interface, with an option to invoke 
an embedded version of the aCGHViewer
©. The 
design is such that the viewer may be used for 
external database queries, while interrogating the 
Overlay Tool
© categorization and the underlying 
raw data. After conﬁ  rming the call results, based 
on the user-selected stringency, the analysis can be 
saved and the data re-analyzed using different 
options. An internet connection is required to 
launch queries against public databases such as 
UCSC Genome Browser via the hyperlinks 
displayed in the summary window.
The Overlay Tool
© currently allows analysis 
of datasets from three categories of microarrays: 
1) copy number changes from either BAC arrays 
or Copy number prediction from the Affymetrix 
GeneChip
® Mapping SNP arrays, 2) Gene expres-
sion profiling from the Affymetrix GeneChip 
expression arrays and 3) LOH probability from 
the Affymetrix GeneChip
® Mapping SNP arrays. 
However, the Overlay Tool
© is constructed to 
support data from virtually any custom array type 
provided that it is supplied with a platform-speciﬁ  c 
annotation ﬁ  le compatible with the Overlay Tool
© 
(Fig. 1F). Currently, the Overlay Tool
© supports 
ﬁ  ve types of overlay: 1) aCGH/expression, 2) SNP 
copy number prediction/expression, 3) aCGH/
LOH probability, 4) LOH probability/expression 
and 5) aCGH/LOH probability/expression 
(Fig. 1A). To avoid clutter, and data overload to 
the user, the output of the Overlay Tool
© displays 
only one primary data type dictated at the user’s 
discretion (Fig. 1E), with concordant changes in 
the complementary platform highlighted by 
changing the data points either red or green 
allowing easy visualization (Figs. 2 and 3).
The Overlay Tool
© also provides multiple, 
user-adjustable, settings which allows individual 
experience/expertise to dictate the stringency used 
when determining concordance and discordance 
between datasets (Fig. 1G, 1H, 1I and 1J). Once 
the comparisons are completed, a graphical user 
interface allows the data that gave rise to the 
concordance/discordance call to be queried by 
entering the gene symbol, as well as launching the 
aCGHViewer
© for graphical display of the genome 
(Fig. 4). 
Processes of the Overlay Tool
© 
At the core, the Overlay Tool
© consists of three major 
parts: Data Format Conversion, Platform-speciﬁ  c 
Data Agreement and ‘cross platform data agreement’ 
(Fig. 5).
Data format conversion
Since each platform has its own unique annotation 
methods and identiﬁ  ers, it was necessary to imple-
ment a data format conversion step to facilitate the 
comparison procedures. For example, the epidermal 
growth factor receptor (EGFR) gene is represented 
by two different BACs on the RPCI 6K BAC array, 
15 Probe Sets on the Affymetrix U133 Plus 2 array 
and 29 SNPs on the Affymetrix Mapping 100K 
SNP array platforms (Table 1). To overcome this 
diversity, we have converted all annotation for a 
single gene into one descriptor—the gene symbol. 310
Lo et al
Cancer Informatics 2007:3 
The input data is then converted using the built-in 
Overlay Tool
© annotation ﬁ  les. Thus, EGFR now 
becomes the new identiﬁ  er which allows data from 
virtually any source to be incorporated. For 
example, all of the associated data points for EGFR 
would then be distilled into two data sets evaluated 
under the ‘EGFR’ identiﬁ  er (Table 1 and 2).
Annotation ﬁ  les for the BAC arrays are generated 
by using the FISH mapping and BAC end sequence 
information (available at http:/hgdownload.cse.ucsc.
edu/goldenPath/hg18/database/) and comparing 
them to the NCBI published positional information 
of the known genes determined by Refseq align-
ment, protein evidence and/or transcript evidence. 
In our speciﬁ  c application, a minimum 30% of the 
gene sequence coverage is required to associate a 
BAC to a gene, which avoids erroneous assignment 
of a gene to a BAC with minimal overlap. 
The associated gene symbol for the Affymetrix 
probe set IDs were used to generate the annotation 
ﬁ  les for the Affymetrix platforms after converting 
them to the HUGO-approved unique identiﬁ  ers. 
This process facilitated identifying those particular 
Affymetrix probe sets that used either a previous 
HUGO symbol or alias as its main identiﬁ  er. When-
ever a particular probe set points to a gene symbol 
that is not unique (either the symbol is both a 
previous symbol of another gene and a current 
approved symbol in the HUGO database), the 
mapping information provided by Affymetrix is 
cross-compared to the HUGO database to manually 
resolve the accepted identiﬁ  er. With the Affymetrix 
mapping SNP arrays, only SNPs that are located 
within 10,000bp of the genomic location of the 
start or the end of a gene are used. Although the 
mapping SNP arrays also provide an estimate of 
copy number at each locus, due to the noise levels 
associated with the SNP array, we felt it was not 
appropriate to use similar inference type evalua-
tions that have been applied to the BAC arrays, 
although the high density nature of the SNP arrays 
provide a more extensive coverage than the BAC 
arrays (see below).
Platform-speciﬁ  c data agreement
BAC arrays
During the development of the Overlay Tool
© 
strategy using the gene-centric approach described 
above, it was necessary to overcome the problem 
that many genes were located in regions of the 
genome that were not represented by a speciﬁ  c 
BAC on lower resolution arrays. As BAC arrays 
become more comprehensive, however, this is 
becoming less of a concern, although many existing 
Figure 1. The graphical user interface for the Overlay Tool
©. This interface allows the choice of overlay type and the array platforms to be 
selected, as well as user-deﬁ  ned threshold values. The various sections as outlined (dotted lines) are designed for user input of the follow-
ing information: (A) Overlay Type, (B) Data Source for array data, (C) Array Platform type, (D) User-deﬁ  ned threshold and Data Center, (E) 
Primary Display Type, (F) Option for users to add Custom Array Types to the Overlay Tool
©, (G) Calculation options for aCGH data, (H) 
Calculation options for SNP array data, (I) Weighting scheme based on probe set sufﬁ  xes for the Affymetrix gene expression arrays and (J) 
Calculation options for Affymetrix gene expression arrays.311
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datasets will still have been derived from lower 
density arrays. To address this issue, genes are 
placed in one of two classes (Internal and in Gap) 
depending on the coverage of the aCGH platform. 
The different category genes are evaluated by 
different mechanisms. From our experience with 
BAC arrays, we found that the noise level was 
acceptable to evaluate these ‘in Gap’ genes by 
essentially inferring the copy number at that locus 
based on the two neighboring BACs present on the 
array.
During the analysis, the Overlay Tool
© imports 
the necessary raw data from the datasets and 
evaluates each data point by comparing this value 
to the user-deﬁ  ned threshold (for non-categorized 
data) and assigns a data point-speciﬁ  c category of 
1 (gain), −1 (loss) or 0 (no change). For categorized 
data, the categories generated by other statistical 
analysis tools are used instead of performing a 
comparison with the user-defined thresholds 
(Fig. 5).
‘I’ Class
The ‘I’ class consists of genes for which at least 30% 
of the coding region is represented by BACs on the 
particular array used (Fig. 6). When multiple BACs 
(aCGH) on the array represent the signal for a 
particular gene, the data point-speciﬁ  c categories 
described above are further evaluated according to 
the user-deﬁ  ned choice of calculation method to 
give a platform-speciﬁ  c summary category (see 
Fig. 5). The current version of the Overlay Tool
© 
has two options for the ‘I’ class: a ‘max-min’ 
approach and a ‘majority’ approach. Both the 
Figure 2. The aCGHViewer
© genomic view of the RPCI 6K BAC Array (A) showing the graphical representation of aCGH data from a ma-
lignant glioblastoma. Notice ampliﬁ  cation of the EGFR locus (circle) on chromosome 7, a homozygous deletion around PTEN locus on 
chromosome 10 (double circle) and a single copy loss of chromosome 10, which are common cytogenetic events associated with glioblas-
toma. In (B), the aCGHViewer
© genomic view of the SLR values from Affymetrix U133Plus2 expression array of the same glioblastoma 
sample is shown. Due to the intra data noise levels, it is difﬁ  cult to establish the relationship between the two datasets (A and B) based on 
visual inspection alone. In C, the aCGHViewer
© genomic view of the LOH p-values of the Affymetrix Mapping 100K SNP Array of the same 
glioblastoma sample is shown. Examples of regions showing high conﬁ  dence of LOH based on pooled normal allelic frequencies are high-
lighted by arrows (not all areas are highlighted to avoid clutter). Note the Y-axis scale differs for each chromosome depending on the range 
of –log p-values which is important for interpretation of LOH (see text).312
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Figure 3. The graphical display of the overlay between aCGH (from the RPCI 6K BAC Array) and gene expression data (from Affymetrix 
U133Plus2 Array) viewed by aCGHViewer
© (A). Notice that numerous data points have either been colored red or green, signifying concor-
dance between the two platforms. Red spots signify genes that show both a gain in copy number using the BAC array and upregulation 
using the U133Plus2 array. Green spots signify genes that show a loss in copy number by the BAC array coinciding with downregulation by 
the U133Plus2 arrays. For more details of the various types of overlay and the different interpretation of the highlighting scheme, see table 3. 
In (B), the Overlay Results displayed by the aCGHViewer
© for chromosome 7 are shown. Red/Green spots represent concordance between 
the aCGH and expression platforms. EGFR has been annotated using the aCGHViewer
© annotation tool. In (C), the overlay results for 
chromosome 10 are shown. PTEN is annotated using the same annotation tool. In both (A) and (B), the primary display data are log 2 ratios 
from the BAC array analysis. Notice that both EGFR and PTEN were highlighted by the Overlay Tool
©.
Figure 4. The summary graphical interface that provides access to the various data points used to generate the cross platform category 
information, as well as providing the option to launch aCGHViewer
©. The Interface also displays the user-deﬁ  ned settings used to generate 
the overlay. A hyperlink is added to the UCSC genome browser for more detailed information. 313
Cross Platform Microarray Analysis
Cancer Informatics 2007:3 
Table 1. Summary of different array identiﬁ  ers for the EGFR gene.
Experiment Type  aCGH  Expression Proﬁ  le  SNP Studies
Array Platform  RPCI 6k BAC Array  U133 Plus 2 Array  Mapping 100K Array
 EGFR   RP11-81B20   1565  483_at   SNP_A-1656548
   RP11-89E8   1565  484_X_at   SNP_A-1656756
     201983_s_at   SNP_A-1663463
     201984_s_at   SNP_A-1665473
     211550_at   SNP_A-1703938
     211551_at╪   SNP_A-1705242╪
╪Since there were 15 probe sets for EGFR on the Affymetrix U133 Plus 2 array, many of these have been omitted to abbreviate the table.
╪Since there were 29 SNPs for EGFR on the Affymetrix Mapping 100K array, the ‘majority’ of have been omitted to abbreviate the table. 
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Figure 5. Schematic summary of the categories generated by the Overlay Tool
© for each gene. Category data is generated at three levels 
(data point-speciﬁ  c category, platform-speciﬁ  c category and gene level summary category). Where statistical analysis is performed on a 
particular platform, the statistical category data selected can be used in the data point-speciﬁ  c category instead of comparing to a user-
deﬁ  ned threshold by choosing the “CAT” option in user-deﬁ  ned threshold.
‘max-min’ approach and the ‘majority’ approach are 
evaluation methods that generate the platform-
specific summary category data based on data 
point-speciﬁ  c categories. If the ‘max-min’ approach’ 
is selected, only one of the data point-specific 
summary categories within the series needs to show 
deviation from ‘no change’ to deﬁ  ne this gene as 
either gained or lost in the platform-specific 
summary category. This approach is more liberal 
than the ‘majority’ approach, where the number of 
data points that have categories of gain/loss must 
outnumber their opposite counterpart to change the 
platform-speciﬁ  c summary category to represent 
that trend. 
‘G’ Class
Unlike the ‘I’ class genes, ‘G’ class genes are not 
speciﬁ  cally interrogated by a speciﬁ  c BAC on the 
array. Due to the consistently high signal to noise 
ratio, an evaluation is based on ‘inferred’ data from 
the neighboring BACs. ‘G’ class genes lie in regions 
of the chromosome which are not covered by a 
speciﬁ  c BAC. However, if two adjacent BACs on the 
array show a CNA, it is inferred that the region 
between them follows the same trend (gain or loss). 
For example, the locus containing the tumor 
suppressor gene, phosphatase and tensin homolog 
(PTEN ), is deleted in a small proportion of malignant 
glioblastomas (Fig. 6). The PTEN gene sequence is 
not speciﬁ  cally represented on the RPCI 6K BAC 
array but is flanked by BACs RP11-79A15 and 
RP11-129G17. The values of the two neighboring 
BACs are ﬁ  rst evaluated either by comparison to 
user-deﬁ  ned thresholds (non-categorized data) or by 
using previously generated categories through 
statistical analysis (categorized data) to give each a 
data point-speciﬁ  c category. The platform-speciﬁ  c 
summary category is then evaluated by either one of 314
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two currently supported approaches: One-Agree 
approach or Both-Agree approach. When the 
‘Both-Agree approach’ is selected, the platform-
speciﬁ  c summary category deviates from ‘no change’ 
only when both of the neighboring BACs have 
concordant data point-speciﬁ  c categories of gain/loss. 
This is contrasted by the One-Agree approach where 
any one of the two BACs showing a trend will 
generate a platform-speciﬁ  c summary category of 
that trend. In our opinion, this evaluation method can 
be dangerously liberal, and while we recognize that 
this approach may not be appropriate in all 
circumstances, we have included this option to be 
used solely in highly speciﬁ  c scenarios. Since we 
have found that the Both-Agree approach may lead 
to the erroneous exclusion of genes residing in gaps 
adjacent to large amplifications, the use of the 
One-Agree approach is valid with the caveat that it 
is applied in the appropriate manner.
Affymetrix gene expression arrays
As the Affymetrix GeneChip platform has evolved, 
the accompanying analysis tools have also changed. 
Various statistical methods have been used throughout 
the analysis process to assess differential expression 
between test and reference samples (i.e. tumor/
normal). While some of these tools are generally 
geared towards analysis at the individual probe level, 
a design decision was made during the development 
of the Overlay Tool
© to analyze data from the probe 
set summary level. This approach provides the ﬂ  ex-
ibility to apply various background correction, outlier 
detection and normalization algorithms. 
3435 33 chr7  (p11.2)
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Figure 6. (A): Genomic location and cytogenetic information of the EGFR gene, a category ‘I’ gene in the RPCI 6K BAC array. Notice EGFR 
is covered by two BACs (RP11-81B20 and RP11-89E8). (B) Genomic location and cytogenetic information of tumor suppressor PTEN, a 
category ‘G’ gene in the RPCI 6K BAC array. Notice PTEN is ﬂ  anked by two speciﬁ  c BACs on the RPCI 6K BAC array: RP11-79A15 and 
RP11-129G17.
Table 2. Values obtained from two high throughput platforms for the EGFR gene.
Experiment Type  aCGH Studies    Expression Studies 
Array Platform  RPCI 6K BAC Array Log2 Ratio   U133 Plus 2 Array  SLR
 EGFR   RP11-81B20   4.41     1565483_at     4.10
   RP11-89E8   4.425     1565484_x_at   2.93
         201983_s_at   4.49
         201984_s_at     4.67
         211550_at      −0.04
         211551_at     0.40
         211607_x_at   4.74
         224999_at     4.66
         232120_at     3.24
         232541_at     4.42
         232925_at     4.58
         233044_at     2.90
         237938_at     1.62
         243327_at     0.45315
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Once the appropriate signal log ratio (SLR) is 
generated between test and reference, the Overlay 
Tool
© ﬁ  rst evaluates each probe set individually 
and generates a data point-speciﬁ  c category exactly 
as it does for the BAC array. However, during 
generation of the gene level summary category, 
there are more user-tunable parameters available 
to adjust the stringency of the analysis of expression 
data. These include: 1) ‘max-min’ approach, 2) 
‘majority’ approach, 3) ‘weighted means’ approach 
and 4) ‘median’ approach, as well as the user-
defined weighing scheme based on probe set 
sufﬁ  xes (Fig. 1I and 1J). 
Since evaluation approaches (1) and (2) have 
been explored earlier, only options (3) and (4) 
warrant clariﬁ  cation here. In the higher density 
Affymetrix arrays, individual genes are often 
represented by multiple probe sets. In any given 
analysis, it is not uncommon that the probe sets for 
a given gene will show variation in SLR values 
and sometimes show an opposite trend. It was 
important, therefore, to provide a mechanism to 
accommodate these eventualities. To reconcile this, 
aside from allowing the same evaluation methods 
for gene-level summary categorization that were 
available in the BAC array, we developed addi-
tional methods to use the ‘center’ (either by way 
of a mean or median) as the value to determine the 
gene-level summary category. These methods 
differ from the previous two in that both the 
‘max-min’ and ‘majority’ approach evaluate gene 
expression levels by looking for outliers, whereas 
the ‘weighted means’ or ‘median’ approach require 
the ‘center’ to pass the user-deﬁ  ned threshold for 
a summary category representing that trend to be 
generated. These methods are considerably more 
stringent than either the ‘max-min’ or ‘majority’ 
approaches, and should be used only when this 
stringency is deemed to be appropriate.
In addition to the various summary category 
generation methods, a user-defined weighing 
scheme can be used based on user experience/
expertise. The Overlay Tool
© provides the oppor-
tunity to weight groups of probe sets (by sufﬁ  xes) 
differently, so that if a particular group of probe 
sets have been found to be unreliable, they can 
effectively be removed from the platform-speciﬁ  c 
summary category consideration. For example, an 
Affymetrix probe set ending with ‘_x_at’ on the 
U133Plus2 platforms, signify that this group of 
probe sets may cross-hybridize in an unpredictable 
manner (Affymetrix Data Analysis Fundamentals, 
2005). If it is desirable to discount these probe sets 
from further analysis, then a weigh of ‘0’ to the 
‘_x_at’ probe sets can be entered into the user-
deﬁ  ned weighing scheme (Fig. 1I). In this case, 
none of the probe sets ending with ‘_x_at’ will be 
considered during platform-specific summary 
category consideration.
Affymetrix mapping SNP arrays
For overlay analysis, only data points that are 
located within 10 kb of the start and end of the 
genomic location of a gene are used for evaluation 
in the Overlay Tool
©. Based on our experience with 
the noise level of the mapping SNP array platform, 
it was not considered appropriate to use similar 
evaluation mechanisms for the genes that fall into 
gaps between data points, as described earlier for 
the BAC arrays. Thus, currently, only genes that 
have direct coverage by the SNP array are evalu-
ated and considered in this application.
The Affymetrix Mapping SNP Arrays can 
generate two different categories of data: copy 
number based on the Copy Number Analysis Tool 
(CNAT) and a LOH probability at each SNP loca-
tion based on pooled normal allelic frequencies. 
The copy number data generated from the mapping 
SNP arrays are treated in ways similar to that 
described for the BAC arrays (with the exception 
discussed above), for which both ‘max-min’ and 
‘majority’ approaches are available. The nature of 
the LOH probability data generated from the 
mapping SNP array, on the other hand, differs from 
the copy number data in that it displays the inverse 
probability that LOH has occurred at any particular 
locus. This data is treated in a similar way, in that 
each data point is compared to the user-deﬁ  ned 
thresholds to generate the data point-specific 
category. After all data points are evaluated, the 
platform-speciﬁ  c summary category is generated 
by one of three evaluation methods: 1) mean p-val, 
2) ‘one agree’ approach and 3) ‘majority’ approach 
(Fig. 1H). A mean p-value approach is similar to 
the ‘weighted means’ for expression, in that a 
calculation of the mean of all the gene-speciﬁ  c data 
points is performed before a comparison with the 
user-defined threshold. The platform-specific 
summary category for LOH is evaluated either as 
1 (likely shows LOH) or 0 (unlikely to show LOH). 
Unlike the ‘one agree’ and ‘majority’ approaches, 
the mean calculation uses the ‘center’ to gauge 
whether this is a good likelihood of LOH or not. 
However, one note of caution is that the default 316
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setting for the Affymetrix Copy Number Analysis 
Tool (CNAT) for genome smoothing is 0.5 Mb, 
which is larger than the average length of a gene. 
Thus, smoothing using this default setting may lead 
to over dampening of the raw data, especially when 
applied on a per gene basis. 
In instances where data stemming from 
different probe sets of a particular gene (either 
expression or SNP array) provides contradictory 
evidence, a platform-speciﬁ  c summary category 
of ‘undetermined’ is given, signifying that 
evidence for both gains or losses are present for 
the particular gene. During the evaluation of the 
cross platform category, ‘undetermined’ will be 
used as a wildcard for drawing concordance/ 
discordance conclusions.
Cross platform data agreement
After each platform has been evaluated for all plat-
form-speciﬁ  c summary categories, an additional 
evaluation is performed to provide a cross platform 
(‘Overlay’) category. When agreement is reached 
between the platforms, an overall category signi-
fying the overall trend is generated for the gene, and 
thus, used to highlight the data point in aCGH-
Viewer
©. Due to the differences in the nature of the 
overlay, the highlighted colors (red or green) require 
different interpretation (Table 3).
In all other instances, where there is either (a) 
no agreement between the platforms, (b) data 
points which do not surpass the user-defined 
thresholds (for non-categorized data), or (c) the 
gene is only covered by one of the platforms, a 
category value of ‘0’ is assigned, signifying that 
no agreement can be reached. The resulting data 
points in these cases will be displayed as black dots 
on aCGHViewer
©.
Details of the evaluation methods
For genes with single data points, all of the 
evaluation methods will generate the same result. 
However, when a gene is represented by multiple 
probes (probe sets), the results could differ 
slightly depending on which evaluation method 
is selected. To show the subtle nuisances of the 
various evaluation methods, we have undertaken 
a preliminary analysis for expression data of one 
gene for user reference. As an example, analysis 
of the EGFR gene demonstrates the changes that 
might be encountered using the different calcula-
tion options. 
Thus, EGFR is represented by multiple probe sets 
on the Affymetrix U133Plus2 platform. Using SAM, 
a two-class unpaired analysis (using a t-test as test 
statistic with 5,000 permutations) was performed 
among samples with and without evidence of copy 
number ampliﬁ  cation of the EGFR locus using the 
BAC array data (Rossi et al. 2005). All probe sets were 
weighted equally and a threshold value of 1.5 (SLR) 
was chosen for this analysis (see Fig. 7). All of the 
methods used for this analysis, regardless of strin-
gency, gave the same result for samples that showed 
Table 3. A brief description of the highlighting convention used for displaying correlations in aCCHViewer using 
output from the overlay tool. Based on the choice of the overlay type, the colors used to highlight concordance 
may signify different types of agreement. This is especially evident for the overlay of aCGH with LOH.  
  Data Points highlights in aCGHViewer
Overlay Type  Red  Green  Black
aCGH/ Gain/  Loss/Downregulation  No  agreement.
Expression  Upregulation       not coverd by all platforms,
    no  change
SNP CN/  Gain/  Loss/Downregulation  No agreement.
Expession  Upregulation       not coverd by all platforms, 
    no  change
aCGH/SNP LOH/  Gain/  Loss/Downregulation/  No agreement. 
Expression  Upregulation/LOH  LOH   not coverd by all platforms, 
    no  change
SNP LOH/  LOH/   LOH/Downregulation  No agreement. 
Expression  Upregulation    not coverd by all platforms,
    no  change
aCGH/SNP LOH  Loss or Gain/  No Loss or no Gain/  No LOH
 LOH  LOH 317
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a physical ampliﬁ  cation, with the exception of one 
tumor sample (#57). Analysis of tumors with no 
ampliﬁ  cation, however, showed a distinct difference 
between the more liberal evaluation methods 
(‘majority’ and ‘max-min’) and the more stringent 
evaluation methods (‘weighted means’ and ‘median’). 
The results from the ‘majority’ and ‘max-min’ evalu-
ation methods indicate that there is, in general, an 
increase in expression, even though there is no ampli-
ﬁ  cation. Using the ‘weighted means’ and ‘median’ 
evaluation methods, increase in expression in any of 
the samples without physical ampliﬁ  cation is not 
detected. However, by weighting the different probe 
set based on their sufﬁ  xes may introduce additional 
changes when generating the platform speciﬁ  c cate-
gory (see Fig. 7).
The biological signiﬁ  cance of the data-analysis 
variation can be explained in one of two ways: 
either there is an upregulation of gene transcript 
levels without physical ampliﬁ  cation of the gene, 
or the categories made by the Overlay Tool
© repre-
sent false discoveries due to the stringency of the 
evaluation method. As such, it might be expected 
that the false discovery rate would decrease with a 
more stringent evaluation method.
Data input requirements
The Overlay Tool
© accepts either a 4- or 5- 
column tab-delimited data set, with an optional 
ﬁ  fth column to include categorical information 
from prior statistical analyses. Only values of 3 
(signifying gain or upregulation), 1 (signifying 
no change) and 2 (signifying loss or downregula-
tion) are acceptable. The ﬁ  rst column contains 
the gene symbol; the second column contains the 
chromosome number information; the third 
column contains the mapping location of the 
gene; and the fourth column contains the value 
of the particular platform. If the delimited text 
ﬁ  le can be displayed with the aCGHViewer
©, the 
formatting will be acceptable to the Overlay 
Tool
©. Two sample data ﬁ  les (6K_BAC_array_
test_data.txt and U133Plus2_test_data.txt) are 
included in the self-extracting zip ﬁ  le for format-
ting reference. 
Data output
Currently, the Overlay Tool
© outputs tab-delimited 
text ﬁ  les for visualization with the option to save 
the analysis as an .olt ﬁ  le. In addition to including 
gene symbol, the chromosome location and the 
chosen primary display value, the Overlay Tool
© 
adds an additional column of data using the cross 
platform category data generated as a result of 
‘cross platform data agreement’ processing. This 
category data is then used to highlight changes 
that stem from agreement between the two plat-
forms and utilizes the ﬂ  agging capacity of the 
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Figure 7. A preliminary evaluation of the differences in calculation methods and their subsequent determination of the platform speciﬁ  c 
category for the EGFR gene. The expression of EGFR is interrogated by multiple probe sets on the Affymetrix Gene-Chip U133 Plus 2 array. 
Samples were segregated by the presence or absence of EGFR ampliﬁ  cation as seen on the BAC arrays (data not shown). Notice in tumor 
samples with EGFR ampliﬁ  cation, all of the evaluation methods show upregulation of EGFR expression, regardless of the choice of calcula-
tion method (with the exception on the ‘median’ approach on tumor #57). Where there is no EGFR ampliﬁ  cation, the choice of calculation 
method has a large impact as to whether the platform speciﬁ  c category is called up, down or no change. However, in the overlay of the 
aCGH platform with expression, those tumor samples without ampliﬁ  cation would yield a cross platform category of “no agreement” and 
thus would not be highlighted in the overlay. 318
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aCGHViewer
© to display the data points as red or 
green (Fig. 3b and 3c). 
Discussion
As high throughput, genome-wide screening using 
microarray technology becomes more common, 
the understanding of the underlying genetics of 
cancer is expected to increase exponentially. While 
aCGH and gene expression proﬁ  ling have inde-
pendently contributed to this understanding, 
additional information can be mined and extracted 
through the complementary use of these high 
throughput platforms. By overlaying the datasets 
between two or more platforms, gene candidates 
can be quickly identiﬁ  ed and prioritized for further 
biological studies. To that end, we have devised 
an approach for performing the overlay of two or 
more datasets by combining the data using a gene-
centric approach, as well as developing software 
to facilitate such an overlay in a time-efﬁ  cient 
manner. Once the data sources for two or more 
platforms are identiﬁ  ed, and all the necessary 
options for launching the Overlay Tool
© are 
selected, it will then perform an overlay of the 
datasets. The aCGHViewer
© can be used to visu-
alize the results of the overlay in addition to a 
summary user-interface for more in-depth inves-
tigation of the Overlay Tool
© algorithm. The 
inherent ﬂ  agging mechanism in aCGHViewer
© 
allows potential candidate genes to be easily iden-
tiﬁ  ed due to the data point highlighting of the 
overlay whenever a concordance is reached 
between two datasets (i.e. ampliﬁ  cation in aCGH 
with overexpression in gene expression). Although 
the development of this application was facilitated 
by specifically using the RPCI BAC arrays, 
Affymetrix GeneChip
® expression arrays and 
Affymetrix GeneChip
® mapping SNP arrays, 
additional custom platforms can easily be included 
in the Overlay Tool
© through the Custom Array 
Platform adding function included in the current 
release. Thus, whenever the annotation ﬁ  le can be 
formatted in a way that is consistent with the other 
annotation ﬁ  les provided with the Overlay Tool
©, 
any platform that can be evaluated using the calcu-
lation options described above can be processed.
Materials and Methods
Figure 5 shows the workﬂ  ow of the RPCI Overlay 
Tool. The program has been implemented in 
Microsoft
® Visual Basic 2005
® using an object-
oriented approach to facilitate future develop-
ments. The basic components of the RPCI Overlay 
Tool
© include the graphical user interface (GUI) 
and summary interface. After the overlay analysis 
is complete, the aCGHviewer can be invoked via 
the summary interface to connect to public data-
bases such as NCBI or UCSC genome browser 
for additional information of gene targets. The 
results of the overlay analysis are outputted into 
a tab-delimited text ﬁ  le for user reference.
Availability
RPCI Overlay Tool
© is freely available for 
academic users for non-commercial purposes at 
http://falcon.roswellpark.org.
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